Oxybral 30mg capsules sustained-release

国: アルメニア

言語: 英語

ソース: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

有効成分:

vincamine

から入手可能:

GlaxoSmithKline S.A.E.

ATCコード:

C04AX07

INN（国際名）:

vincamine

投薬量:

30mg

医薬品形態:

capsules sustained-release

パッケージ内のユニット:

(20/2x10/) blisters

処方タイプ:

Prescription

認証ステータス:

Registered

承認日:

2015-05-15

製品の特徴

SMPC FOR OXYBRAL (VINCAMINE)
NAME OF THE MEDICINAL PRODUCT
Oxybral, sustained release capsule, 30 mg
QUALITATIVE AND QUANTITATIVE COMPOSITION
_Vincamine, sustained release capsule, 30 mg _
Each sustained release capsule contains 30 mg of vincamine
EXCIPIENTS
_Vincamine, sustained release capsule, 30 mg _
Sugar microspheres, Lactose, Methacrylic acid co- polymer, (Eudragit
L), Povidone,
Shellac, Talc, Gelatin, Erythrosine [E127], Indigotine (E 132)
PHARMACEUTICAL FORM
_Vincamine, sustained release capsule, 30 mg _
Hard gelatin capsules; colourless, transparent body and blue lid;
capsule content: white
microspheres.
CLINICAL INFORMATION
INDICATIONS
Vincamine is indicated to normalize and adapt the cerebral blood flow
according to the
metabolic needs and in turn improves, regulates and maintains all the
brain functions,
reflecting better performance physically and intellectually.

Cerebral disorders in the elderly, such as:

memory disorders

concentration disorders

attention and perception disorders

Degenerative trophic disorders:

diabetes mellitus

atherosclerosis

After acute cerebral injury:

post-traumatic

post-apoplectic

hypertensive encephalopathy

Dizziness, vertigo, headaches of vascular origin and migraine

Hearing disorders of vascular origin

Visual disorders of vascular origin

Mental disorders:

temporal and spatial orientation

mood disorders

cerebro-vascular disorders, particularly cerebral ischemia

Improving the intellectual capacity
DOSAGE AND ADMINISTRATION
ROUTE OF ADMINISTRATION
_Vincamine, sustained release capsule, 30 mg _
For oral use
ADULTS AND ELDERLY
_Vincamine, sustained release capsule, 30 mg _
One capsule twice daily
RENAL IMPAIRMENT
There are no relevant data available.
HEPATIC IMPAIRMENT
Although an impairment of the hepatic function was not observed, it
should be monitored
in long-term vincamine treatment.
CONTRAINDICATIONS
Vincamine is contraindicated in:

intracranial tumors (or diseases related to increased intracr